News

Custom Ink Welcomes Ryan Massimo as New Chief Revenue Officer

Custom Ink Welcomes Ryan Massimo as New Chief Revenue Officer

Custom Ink Appoints New Chief Revenue Officer

Custom Ink, a frontrunner in the online custom products and apparel sector, has taken a significant step in its leadership with the appointment of Ryan Massimo as Chief Revenue Officer. With two decades of experience in enterprise sales and strategy, Massimo's journey through top companies like Vistaprint, Dell, and ezCater has prepared him for this pivotal role.

Understanding Ryan Massimo's Role at Custom Ink

As Chief Revenue Officer, Massimo will spearhead the sales strategies for Custom Ink, focusing on driving revenue growth and developing a high-performance sales organization. His hands-on approach will involve crafting data-driven sales initiatives aimed at optimizing how the company attracts and retains customers. He will also collaborate closely with the product team to enhance customer service throughout various sales channels. Reporting directly to CEO David Doctorow, Massimo will play a crucial role in shaping the future of Custom Ink.

Massimo's Impressive Background

David Doctorow, CEO of Custom Ink, praised Massimo's extensive background, mentioning, "Ryan is a seasoned go-to-market leader with a track record of building and scaling high-performing sales and marketing organizations. He has led critical growth initiatives at Dell, Vistaprint, and ezCater, driving transformation across multiple industries." This extensive experience is expected to empower the revenue team and help meet ambitious business goals.

Historical Impact in Sales and Strategy

During his tenure at Dell, Massimo developed several business initiatives including the launch of the company's first Loyalty program. His strategic leadership in the Consumer & Small Business division helped lift the company's competitive edge in a challenging market. At Vistaprint, he was a key player in the company's global transformation, propelling the corporate sales team into new heights.

Transformative Achievements at ezCater

Most recently, at ezCater, Massimo oversaw a remarkable growth trajectory for the B2B sales division, bringing annual revenue up from $10 million to an impressive $400 million. This accomplishment helped cement ezCater's position as a leader in workplace food solutions, showcasing his effectiveness in scaling sales operations.

Strengthening the Leadership at Custom Ink

Massimo joins a growing executive team at Custom Ink, which has seen significant changes this year. Under the leadership of CEO Doctorow, the company has welcomed several new members, including Arthur Chapin and Bailey Rockwell Adrian in pivotal roles that shape the company’s product and customer experience strategies. Additionally, the recent arrival of Ben Litvinas as Chief Data and Analytics Officer (CDAO) reflects Custom Ink's commitment to harnessing data for driving innovation and efficiency.

About Custom Ink

Based strategically in Tysons, Virginia, Custom Ink has established itself as the online leader in custom products and apparel. The company is dedicated to creating a sense of community and camaraderie among groups and businesses by providing custom items that people are excited to use and wear. Their approach emphasizes innovative design, exceptional customer service, and a diverse range of high-quality merchandise, making the process seamless and enjoyable.

For inquiries, Custom Ink can be reached through Andrew Weinstein at 202-667-4967.

Frequently Asked Questions

Who is Ryan Massimo?

Ryan Massimo is the newly appointed Chief Revenue Officer of Custom Ink, with extensive experience in enterprise sales.

What will Massimo's role involve at Custom Ink?

He will lead sales strategies, optimize customer acquisition, and enhance customer retention.

What companies did Massimo work for before Custom Ink?

He held significant positions at Dell, Vistaprint, and ezCater.

What major achievement did Massimo accomplish at ezCater?

He scaled corporate sales from $10 million to over $400 million annually.

What is Custom Ink known for?

Custom Ink specializes in custom products and apparel for businesses and organizations, emphasizing quality and customer satisfaction.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 5

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 14

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading

Top 5 Most Recently Viewed Articles

PARRIS Law Firm Triumphs in Landmark Billing Case Against Edison

Updated Category News Views 258

PARRIS Law Firm Achieves Major Victory in Consumer Lawsuit The PARRIS Law Firm has recently celebrated a significant win for consumers in a landmark lawsuit against Southern California Edison Company. This case, referencing the Wellman v. Southern California Edison Company, has captured media attention, notably from The Daily Journal, showcasing the firm’s commitment to...

Continue Reading
Intercont (Cayman) Limited's Growth: Exploring Recent Financials

Updated Category News Views 112

Intercont (Cayman) Limited Unveils Financial Results Intercont (Cayman) Limited (NASDAQ: NCT), a prominent leader in the global shipping industry, has shared its financial results for the first half of the fiscal year. The company, renowned for its innovative approach to seaborne pulping operations, reported notable advancements in its financial performance, reflecting...

Continue Reading
What to Expect from Quanex Building Products' Earnings Report

Updated Category News Views 107

Understanding the Upcoming Earnings of Quanex Building Products Quanex Building Products (NASDAQ: NX) is gearing up to announce its quarterly earnings. This moment has been highly anticipated by investors eager to gain insights into the company's financial health. While specific dates are typically essential to focus on, the critical takeaway for investors is the...

Continue Reading
ZERO Fresh Start: RAVEN2's New Era Begins Sept 15

Updated Category News Views 18

What's the Big Deal with ZERO? Alright, so here we go, folks—Netmarble's strapping in with their latest server for RAVEN2, and it's called ZERO. Ever heard of fresh starts? ZERO is exactly that. This isn't your usual server shuffle. Lads and ladies who've felt the grind’ll tell you, ZERO's introducing a slew of changes you might want to sit up for. Pre-registration's...

Continue Reading
Innovative Cancer Treatments: CMU and Healthcare System Lead the Way

Updated Category News Views 266

Revolutionizing Cancer Treatment China Medical University (CMU) and Healthcare System are making significant strides in the field of cancer treatment, notably through AI-driven drug discovery and innovative therapies. At a recent healthcare exposition, these organizations showcased their leading-edge advancements, establishing themselves as pioneers in healthcare...

Continue Reading